A research team at Rutgers University in New Jersey, USA, reported in the Medical Journal (Med) that a vaccine absorbed into the lungs has already tried to induce immunity in the bloodstream through experiments in mice or primates. It is said that phage-vaccine, which rewrites to specific protein molecules, can be used to activate an immune response within cells that recognizes viral threats.
Phage vaccine itself has already attracted steadily attention as an antibiotic replacement therapy. The research team succeeded in developing a new spray-type phage vaccine. It is said that certain protein molecules that bind to lung cell receptors are sent as an aerosol to the lungs, allowing them to travel through the bloodstream and help strengthen immunity in the body.
Experiments have demonstrated that the new inhaled phage vaccine does not impair normal lung function. However, until the end, the experiment is only in the early stage, and the lung function is complicated, so it is still a long time before the test to see if it is safe for the human body.
Nevertheless, the greatest advantage of this vaccine is that it can be mass-produced inexpensively and that storage does not require an extremely cold environment. The mRNA vaccine developed by Biotech and Pfizer is subject to cryogenic storage at -70°C or 80°C. The advantage of not needing these things can be said to be surprisingly large.
If the era comes when a vaccine can be vaccinated by simply inhaling it through the nose and mouth without getting sick injections, expectations can be raised as a new treatment for respiratory diseases such as asthma as well as countermeasures against the Corona 19 virus. Related information can be found here .